论文部分内容阅读
目的:探究益赛普联合柳氮磺吡啶治疗类风湿性关节炎的临床效果观察。方法:资料选自2011年10月-2013年10月在本院诊治的类风湿性关节炎患者80例,按照随机数字表方法分成两组,每组40例,予柳氮磺吡啶作对照组,予以益赛普联合柳氮磺吡啶作研究组,分析两组疗效和不良反应。结果:研究组有效率97.50%,比对照组82.50%高,比较差异明显(P<0.05);且研究组头晕、恶心、皮疹等不良反应7.50%,比对照组22.50%少,比较具统计学上的意义(P<0.05)。结论:对类风湿性关节炎予柳氮磺吡啶联合益赛普的疗效显著,具有一定临床应用和研究价值。
Objective: To investigate the clinical effect of Yi Sip combined with sulfasalazine in the treatment of rheumatoid arthritis. Methods: The data were collected from 80 patients with rheumatoid arthritis who were diagnosed and treated in our hospital from October 2011 to October 2013. The patients were divided into two groups according to the random number table (40 patients in each group), and the control group was given sulfasalazine , Yi Sip combined sulfasalazine as a research group, analysis of two groups efficacy and adverse reactions. Results: The effective rate of the study group was 97.50%, which was significantly higher than that of the control group (82.50%) (P <0.05). The adverse reaction such as dizziness, nausea and rash in the study group was 7.50%, less than 22.50% in the control group The significance (P <0.05). Conclusion: The curative effect of sulfasalazine combined with etanercept on rheumatoid arthritis is significant and has certain clinical application and research value.